Accelerating enzyme optimization through an integrated design-to-function workflow
Tuesday, December 2, at 15:00 GMT | 16:00 CET | 10:00 EST | 7:00 PST
Join us for an exclusive webinar hosted by Ribbon Bio, featuring Scala Biodesign and Nuclera, to explore a fully connected “Design–Build–Test–Learn” pipeline for enzyme optimization. Using a DNA-binding enzyme as a case study, the session will demonstrate how AI-based protein design, advanced synthetic DNA assembly, and rapid expression technologies can converge to accelerate discovery and validation of functional enzyme variants.
The speakers will guide participants through each stage, from target identification and in silico optimization to DNA synthesis and expression screening, to functional evaluation of improved variants. Attendees will gain first-hand insight into how this cross-platform workflow can dramatically reduce R&D timelines while increasing confidence in candidate selection.
Key learning objectives:
- Understand how AI-driven design can generate targeted enzyme variants optimized for activity, stability, or specificity.
- Learn how high-accuracy synthetic DNA enables fast, seamless build phases for even complex or repetitive constructs.
- Explore how benchtop protein expression systems streamline screening and upscaling of variant libraries.
- See how an integrated “design–build–test” approach shortens the time from gene to function and de-risks enzyme development projects.
Who should attend?
- Scientists and engineers in enzyme engineering, synthetic biology, and biocatalysis
- R&D leaders in pharma, biotech, and industrial biotech exploring rapid protein optimization
- Researchers working on DNA-binding proteins, transcription factors, or enzyme characterization
- Business development and innovation managers seeking strategic technology collaborations in the design–make–test space
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Speakers
Jodi brings over 18 years of experience leading high-performing commercial teams in the genomics market. She has a proven track record in building industry-leading organizations focused on operational efficiency and high-growth performance. As CEO of Ribbon Bio, she previously served as Chief Business Officer, where she built foundational commercial and product management infrastructure. Before joining Ribbon Bio, Jodi held executive roles at Agilent Technologies, overseeing global commercial operations and marketing for the Diagnostics and Genomics Divisions. She also led product management at Qiagen and field consulting for Roche Diagnostics’ OEM business. Jodi began her career as a bench scientist before moving into commercial leadership. She holds a degree in Molecular and Microbiology from Purdue University and conducted her master’s research in cancer biology.
Dr. Ravit Netzer is the Co-Founder and CEO of Scala Biodesign, a computational protein design startup that launched the ScalaOS platform. ScalaOS designs superior proteins with greater speed and accuracy, resulting in shorter time to market and higher success rates. Scala’s platform combines atomistic modelling, evolutionary data, and AI to create high-performance proteins in a single design round, introducing multiple beneficial mutations to enhance stability and activity without repeated cycles.
Michael Chen is the co-founder and CEO of Nuclera, a Cambridge (UK) and Boston (US) based life science tools company revolutionizing protein accessibility through the eProtein Discovery rapid protein access benchtop platform. With a mission to improve human health, Michael and his classmates founded Nuclera in response to the costly barriers to protein access for research and drug discovery. As CEO, he drives core inventions, sets the company's vision and strategy, and oversees its growth across two continents with over 100 employees. Before Nuclera, Michael was an award-winning structural biologist. His work resulted in numerous high-impact publications including Nature. Michael holds a BSc in Chemistry from the Georgia Institute of Technology and a PhD in Structural Biology/Chemistry from the University of Cambridge and the National Institutes of Health.
Moderator
